TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25552402
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 5 mg after ≥ 10 h fasting with a high‐fat meal at 4 h post‐dose (Treatment C)
Study: 25552402
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 5 mg after a high‐fat meal at 4 h post-dose (Treatment C)
Study: 25552402
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B) and after ≥ 10 h fasting with a high‐fat meal at 4 h post-dose (Treatment C)
Study: 17116685
Drug: Three antimalarial
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three antimalarial treatments
Study: 8506440
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 to 5 mg
Study: 8506440
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 to 100 mg
Study: 8506440
Drug: Diastolic ambulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diastolic ambulatory daily values
Study: 29194927
Drug: Computer guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer guided sinus floor elevation through lateral window approach with simultaneous implant placement
Study: 29194927
Drug: Standard sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sinus elevation procedure through lateral window approach with simultaneous implant placement
Study: 27565012
Drug: Acute dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute dose of alcohol (0.8 g/kg)
Study: 16953457
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg co-administered with omeprazole 20 mg
Study: 8923853
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (constant dose 4 IU/m2 b.s.)
Study: 3905218
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 100 mg/day
Study: 29879602
Drug: Antipsychotic blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic blood levels (ABLs)
Study: 29879602
Drug: No antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antipsychotic blood levels (ABLs)
Study: 26444072
Drug: ITI-007 60
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-007 60 mg
Study: 26444072
Drug: ITI-007 120
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-007 120 mg
Study: 26444072
Drug: ITI-007 60
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-007 60 mg and 120 mg
Study: 23743471
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (400 micrograms)
Study: 17645503
Drug: Annual screens
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test)
Study: 9874808
Drug: Celecoxib (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100, 400, or 800 mg)
Study: 9874808
Drug: Celecoxib (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100-800 mg)
Study: 28903767
Drug: Pessary containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary containing amphoteric tenside (WO3191) after metronidazole treatment
Study: 22074122
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily for 24 weeks
Study: 22074122
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg once daily for 24 weeks
Study: 19765769
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (20 mEq) ingested daily by International Space Station crew members
Study: 2872808
Drug: Terazosin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin with beta blocker plus diuretic
Study: 2872808
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with beta blocker plus diuretic
Study: 2872808
Drug: Terazosin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin with other antihypertensive drugs
Study: 2872808
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with other antihypertensive drugs
Study: 29081255
Drug: Benda‐14 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benda‐14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles)
Study: 18789533
Drug: Distance activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distance activities during 2 hours of daily patching
Study: 18789533
Drug: Near activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near activities during 2 hours of daily patching
Study: 18789533
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching (for children with severe amblyopia)
Study: 9180977
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (4 mg) administered 1 hour before induction and additional doses at 8 and 16 hours later
Study: 9180977
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (5 mg) administered under the same conditions
Study: 15688822
Drug: Adjuvant intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraperitoneal chemotherapy with 50 mg of cisplatinum for washing the peritoneal cavity and 20 mg/m2 of cisplatinum intraperitoneally for the first four days after surgery.
Study: 15688822
Drug: Adjuvant intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraperitoneal chemotherapy.
Study: 7863464
Drug: Cloricromene (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloricromene (100mg gastroresistant capsules twice a day for 7 days)
Study: 406300
Drug: Intranasal cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cromolyn sodium solution (4% solution, 5.2 mg into each nostril 6 times daily)
Study: 31519202
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of POST treatment means method
Study: 25648379
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide anesthesia (2 L/min nitrous oxide and 1 L/min oxygen)
Study: 25648379
Drug: Nitrous oxide-free
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide-free anesthesia (2 L/min air and 1 L/min oxygen)
Study: 19659979
Drug: Thalidomide at
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at a dose of 300 mg/day for 1 week, gradually reduced thereafter.
Study: 19659979
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily for 2 weeks, tapered by 10 mg every 2 weeks.
Study: 15307695
Drug: Qilian decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilian decoction (QLD) given orally, one dose taken twice a day
Study: 15307695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hypoglycemic agent in routine)
Study: 9280714
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 mg/d)
Study: 9280714
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg/d)
Study: 8343915
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA cream (25 mg/mL of lidocaine and prilocaine)
Study: 2883575
Drug: enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (2.5 to 40 mg per day)
Study: 31925970
Drug: Human disease
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human disease network (HDN) analysis of disease treatment cost
Study: 31231923
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (Zostrix HP 0.075%) only (CAP)
Study: 31231923
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin with preheating (CAP + HEAT)
Study: 31231923
Drug: Topical nonsensitizing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nonsensitizing placebo cream (CON)
Study: 26323444
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine (CHX) digluconate and 0.05% cetylpyridinium chloride (CPC) solution
Study: 23518704
Drug: Drain antisepsis
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drain antisepsis (chlorhexidine disc at drain exit site and irrigation with dilute sodium hypochlorite solution)
Study: 23518704
Drug: Standard drain
Normalized name: Standard Drainable Pouch One Piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drain care (twice daily cleansing with alcohol swabs)
Study: 19252449
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salt solutions containing rice
Study: 19252449
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salt solutions containing amylase-resistant starch
Study: 19252449
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salt solutions containing glucose
Study: 9450156
Drug: pivagabine, 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivagabine, 900 mg/d for 90 days
Study: 28671856
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin AUC 6 plus paclitaxel 175 mg/m2 every 3 weeks)
Study: 28671856
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice chemotherapy (ICC)
Study: 27392256
Drug: Internet program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet program 'Lose It' (recording daily calories and physical activity)
Study: 27392256
Drug: Daily wellness
Normalized name: AllerLife Sleep Daily Wellness Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily wellness program (health tips delivered via e-mail)
Study: 22520532
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received enhanced in‐hospital counseling, attention to adherence barriers, communication of discharge medications to community pharmacists and physicians, and ongoing assessment of adherence by community pharmacists.
Study: 18632105
Drug: Methotrexate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (30 mg/m2 intramuscularly weekly)
Study: 18632105
Drug: Actinomycin D
Normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actinomycin D (1.25 mg/m2 intravenous bolus every 2 weeks)
Study: 16837736
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 750 mg
Study: 24355040
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg
Study: 16837736
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg + Norethisterone enanthate (NETE) 200 mg
Study: 7982257
Drug: Uni-Dur (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uni-Dur (600 mg once daily for 5 doses)
Study: 7982257
Drug: Theo-Dur (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (300 mg twice daily for 10 doses)
Study: 3276446
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG) in association with antibiotics
Study: 31724353
Drug: SU Jia-fu's
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at the governor vessel, twice a week for 8 weeks.
Study: 23818201
Drug: Gastrosis No.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrosis No.1 compound (Chinese herbal medicine)
Study: 19797813
Drug: Sago gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sago gel (SG)
Study: 15137922
Drug: 3R,3'R-zeaxanthin dipalmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3R,3'R-zeaxanthin dipalmitate (5 mg)
Study: 15137922
Drug: non-esterified 3R,3'R-zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-esterified 3R,3'R-zeaxanthin (5 mg)
Study: 8093139
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluvastatin
Study: 8093139
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluvastatin
Study: 8093139
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluvastatin plus 8 g cholestyramine
Study: 8093139
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluvastatin plus 8 g cholestyramine
Study: 8093139
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g cholestyramine in combination groups
Study: 25975733
Drug: Basic bladder
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic bladder advice for 1 month followed by alarm therapy (group A)
Study: 25975733
Drug: Alarm therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm therapy only (group B)
Study: 23139373
Drug: Taspoglutide 10
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 10 mg weekly
Study: 23139373
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg weekly
Study: 19130937
Drug: SQ-standardized grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-standardized grass allergen tablet (Grazax)
Study: 16469980
Drug: Butter high
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter high in vaccenic acid (3.6 g vaccenic acid/d)
Study: 7759830
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g intravenously (group P)
Study: 7759830
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g with sulbactam 2 g intravenously (group SP)
Study: 80579
Drug: Naloxone (as
Normalized name: Naloxone (as naloxone hydrochloride) 1.8 mg/actuation nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (as second drug)
Study: 28185713
Drug: Low-dose pitavastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pitavastatin (2 mg/d)
Study: 23093223
Drug: D-serine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (30 mg/kg) + CRT (5 h/week)
Study: 22118312
Drug: Topical cromolyn
Normalized name: cromolyn Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cromolyn sodium 2% ophthalmic solution without 0.01% benzalkonium chloride (BAK)
Study: 22118312
Drug: Topical cromolyn
Normalized name: cromolyn Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cromolyn sodium 2% ophthalmic solution with 0.01% benzalkonium chloride (BAK)
Study: 19189907
Drug: Nurse discharge
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse discharge advocate intervention with follow-up appointments, medication reconciliation, and patient education
Study: 8404943
Drug: Taprostene (6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taprostene (6.25, 12.5, or 25.0 ng.kg‐1 x min‐1) infused for 48 hours followed by a 24-hour tapering period.
Study: 8404943
Drug: Placebo infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infused for 48 hours followed by a 24-hour tapering period.
Study: 31099402
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks + topical corticosteroids (TCS)
Study: 31099402
Drug: Cyclosporine +
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine + topical corticosteroids (TCS)
Study: 21565530
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg at the induction of anesthesia and at the initiation of CPB)
Study: 14656250
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin B12
Study: 14656250
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL saline placebo
Study: 11429358
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg IV nalbuphine (n = 91)
Study: 11429358
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg IV propofol (n = 90)
Study: 7998585
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg orally daily (Group 1)
Study: 7998585
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg every other day (Group 2)
Study: 7998585
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg at the end of each dialysis session (Group 3)
Study: 7998585
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg daily (Group 1)
Study: 3377142
Drug: Inhaled dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled dipyridamole
Study: 31205187
Drug: PF‐02545920 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐02545920 5 mg
Study: 31205187
Drug: PF‐02545920 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐02545920 15 mg
Study: 15483411
Drug: Low-dose albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose albumin (control group)
Study: 15483411
Drug: Moderate-dose albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose albumin (control group)
Study: 9081352
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) at a dose of 33 Gy/11 fractions (45 patients) and 25 Gy/11 fractions (112 patients)
Study: 1670734
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken at least once during the week before the first symptom
Study: 1670734
Drug: Paracetamol, propyphenazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol, propyphenazone, and dipyrone
Study: 6339708
Drug: Single-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose amoxicillin therapy
Study: 6339708
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (10-day course of amoxicillin)
Study: 6339708
Drug: Antibody-coated bacteria
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-coated bacteria assay
Study: 31864884
Drug: Knowledge test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge test administered to pharmacists.
Study: 28426350
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance 25 mg/d for 21 days of every 28-day cycle for 24 months
Study: 18046048
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral testosterone enanthate (TE) twice daily plus 0.5 mg dutasteride daily
Study: 18046048
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral testosterone enanthate (TE) once daily plus 0.5 mg dutasteride daily
Study: 15271105
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dorzolamide-timolol (Cosopt)
Study: 15271105
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of 2% dorzolamide and 0.5% timolol
Study: 15271105
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dorzolamide-timolol (Cosopt) in replacement study
Study: 1614074
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg, single oral dose)
Study: 6540130
Drug: IgG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG therapy
Study: 3487296
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of verapamil prior to aortic cross‐clamping (Group 1)
Study: 3487296
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil plus verapamil in the cardioplegic solution (Group 2)
Study: 3487296
Drug: Verapamil in
Normalized name: verapamil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil in the cardioplegic solution only (Group 3)